News | Radiation Therapy | May 20, 2019

Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer

New clinical data shows certain patients get similar results with five days of consecutive targeted treatment versus four to six weeks

Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer

May 20, 2019 — Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early-stage breast cancer, according to new clinical data. The data was derived from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).

This randomized, phase 3 study compared whole breast irradiation with partial breast irradiation in a large group of women with stage 0, 1 or 2 breast cancer. More than 4,200 patients were enrolled in the trial as part of NRG Oncology cooperative group clinical trial.

Study results showed that while partial breast irradiation does not produce equivalent cancer control for all breast cancer patients with stage 0, 1 and 2 disease, it should still be considered as an alternative for women with DCIS (ductal carcinoma in situ) and early-stage breast cancers deemed “low risk,” based on other tumor characteristics.

When looking at the entire study population, women who received partial breast irradiation experienced a 4.6 percent recurrence rate. Those who underwent whole breast irradiation experienced at 3.9 percent rate of recurrence. Toxicity from treatment was similar, as well as the risk for secondary cancers.

However, researchers also looked at how this played out in subsegments of the population and found that rates of recurrence were nearly identical for women with DCIS, regardless of whether they received whole or partial breast irradiation. This was also true for women with breast cancer classified as low-risk, based on the American Society for Radiation Oncology (ASTRO) clinical guidelines.

Researchers showed that in this subsegment of breast cancer patients, the likelihood of recurrence 10 years post-treatment was very low overall and almost identical between women who received whole breast irradiation (2.3 percent) and partial breast irradiation (2.7 percent).

Julia White, M.D., co-principal investigator of the national trial and head of breast radiation oncology at the OSUCCC – James said this is very important because it reduces the burden of care for women who can still achieve cancer control with fewer treatments, over a shorter period of time.

“A significant portion of the breast cancer patient population nationally – about 25,000 to 30,000 women — would qualify for partial breast irradiation. This is tremendously important because it allows us to give women the right amount of treatment for her disease, and potentially allowing better access to effective breast conservation for those who live far from a radiation facility. Partial breast irradiation can also be delivered in five consecutive days versus whole breast, which can involve four to six consecutive weeks of multi-day treatment. There is no denying that the five day treatment is less costly and disruptive to life,” said White.

At the OSUCCC – James, breast radiation is also delivered in the face down (prone) position to reduce radiation exposure in the chest wall, which has been linked to increased risk of heart and lung disease post cancer treatment.

Data from this NRG Oncology study will be presented at the 2019 American Society of Clinical Oncology Annual Meeting, May 31-June 4 in Chicago.

Watch the VIDEO: Whole Versus Partial Radiotherapy for Breast Cancer

For more information: www.cancer.osu.edu

 

Reference

1. Ganz P.A., Cecchini R.S., White J.R., et al. Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. Presented at ASCO 2019. J Clin Oncol 37, 2019 (suppl; abstr 508)

Related Content

Isoray to Spotlight Cesium-131 Advances at ASTRO Annual Meeting
News | Brachytherapy Systems | September 13, 2019
Isoray Inc. announced it will spotlight the growing cancer treatment applications of Cesium-131 brachytherapy at the...
Akesis Galaxy SRS System Receives FDA 510(k) Clearance
Technology | Radiation Therapy | September 13, 2019
The Akesis Galaxy, a gamma stereotactic radiosurgery system (SRS) with continuous 360-degree rotational technology, has...
Philips Showcases Integrated Radiation Oncology Portfolio at ASTRO 2019
News | Radiation Oncology | September 13, 2019
Philips will showcase its integrated radiation oncology portfolio at the American Society of Radiation Oncology (ASTRO...
RefleXion Highlights Novel Approach to Radiotherapy at ASTRO 2019

The RefleXion X1 Machine without the Gantry Cover. The patented technology incorporates PET imaging data, which enables tumors to continuously signal their location. Image courtesy of Reflexion Medical.

News | Radiation Therapy | September 12, 2019
Therapeutic oncology company RefleXion Medical announced it will showcase the RefleXion X1 Machine at the American...
IBA Dosimetry Releases myQA Machines Software at ASTRO 2019
Technology | Quality Assurance (QA) | September 12, 2019
IBA Dosimetry GmbH announced the launch of the new enhanced myQA Machines 2019 software environment at the upcoming...
ASTRO 2019 to Feature Clinical Experience and Patient Outcomes With Viewray MRIdian
News | Image Guided Radiation Therapy (IGRT) | September 11, 2019
ViewRay Inc. announced that the company's MRIdian and MRIdian Linac magnetic resonance imaging (MRI)-guided radiation...
RadCalc 3D Monte Carlo Calculations for Photons Begins Beta Testing
News | Radiation Therapy | September 11, 2019
RadCalc version 7.1 with the Monte Carlo 3-D module has been released for beta testing to members of the beta testing...
iCAD's ProFound AI Wins Best New Radiology Solution in 2019 MedTech Breakthrough Awards
News | Computer-Aided Detection Software | September 09, 2019
iCAD Inc. announced MedTech Breakthrough, an independent organization that recognizes the top companies and solutions...
Accuray to Display Motion Synchronization Cancer Treatment Technologies at ASTRO 2019
News | Radiation Therapy | September 09, 2019
Accuray announced that it will showcase its motion-synchronization cancer treatment technologies at the upcoming 2019...
A smart algorithm has been trained on a neural network to recognize the appearance of breast cancer in MR images

A smart algorithm has been trained on a neural network to recognize the appearance of breast cancer in MR images. The algorithm, described at the SBI/ACR Breast Imaging Symposium, used deep learning, a form of machine learning, which is a type of artificial intelligence. Image courtesy of Sarah Eskreis-Winkler, M.D.

Feature | Society of Breast Imaging (SBI) | September 06, 2019 | By Greg Freiherr
The use of smart algorithms has the potential to make healthcare more efficient.